In this video we discuss 3-year results of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma.
Caroline Robert, MD, PhD
Advertisement
Articles by Caroline Robert, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Navigating New Horizons in Neuroendocrine Prostate Cancer
3
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
4
The Intersection of Technology and Psycho-Oncology Care
5